Lumos Pharma | NLNK - Zahlungsmittel Und Äquivalente



Zahlungsmittel Und Äquivalente Veränderung Datum
Agenus USD 35M 32M 2026-03
Alterity Therapeutics Limited AUD 15.77M 9.56M 2023-06
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Capricor Therapeutics USD 105.42M 182.42M 2026-03
Celldex Therapeutics USD 35.73M 6.86M 2026-03
Cipla INR 7.96B 39.9M 2025-09
Clal Biotechnology ILS 5.73M 1.71M 2023-12
Compugen USD 90.6M 83.14M 2025-12
CSL USD 2.16B 633M 2025-06
Eli Lilly USD 5.28B 1.99B 2026-03
Grifols EUR 979.78M 334.84M 2024-12
Incyte USD 4.02B 435.22M 2026-03
Intrexon USD 9.34M 1.77M 2024-06
Merck USD 5.33B 9.24B 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Pfizer USD 1.7B 561M 2026-03
Prothena USD 329.46M 21.93M 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03